MedPath

Efficacy and Safety With Ziprasidone in First-episode Psychosis

Phase 4
Completed
Conditions
First Episode Psychosis
Registration Number
NCT01157559
Lead Sponsor
Chonbuk National University Hospital
Brief Summary

The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Patients who meet DSM-IV criteria for first episode schizophrenia, schizophreniform disorder and schizoaffective disorder
Exclusion Criteria
  • Patients with previously prescribed antipsychotic medication in 2 weeks or more
  • patients with substance-induced psychotic disorder, serious suicide attempt, neurological disorder, etc.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Symptoms assessment by objective rating scalesweek 8

PANSS total score, SANS, clinical global impression scale, GAF, DAS-S

Secondary Outcome Measures
NameTimeMethod
Assessment of adverse events by objective rating scales and self report scalestwo-month.

Simpson and Angus rating scale, Barnes Akathisia rating scale and Abnormal Involuntary Movement Scale

Trial Locations

Locations (3)

Heo psychiatric Hospital

🇰🇷

Jeonju, Korea, Republic of

Jeonju Jesus Hospital

🇰🇷

Jeonju, Korea, Republic of

Department of Psychiatry, Chonbuk national University Hospital

🇰🇷

Jeonju, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath